Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018

Overview

Journal Ochsner J

Specialty General Medicine

Date 2018 Dec 19

PMID 30559623

Citations 24

Authors

Tanvir F Kabir

Aman Chauhan

Lowell Anthony

Gerhard C Hildebrandt

Affiliations

Soon will be listed here.

Abstract

Background: Checkpoint inhibitors have transformed the treatment of cancer in adults. This class of drugs has demonstrated encouraging results in various malignancies such as metastatic melanoma, bladder cancer, renal cancer, and non-small cell lung carcinoma. However, researchers have only begun investigating the effectiveness and tolerability of checkpoint inhibitors in pediatric patients.

Methods: We conducted a review of PubMed indexed literature and clinicaltrials.gov using combinations of the keywords checkpoint, inhibitor, pediatric, CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death-1), and PD-L1 (programmed cell death receptor-1 ligand) to find every recently completed and ongoing trial evaluating checkpoint inhibitors in patients younger than 21 years old. Pertinent articles and clinical trials discussing the role of immune checkpoint inhibitors in the pediatric population were selected for final analysis and manuscript citation.

Results: This review presents an overview of the cellular mechanisms involved in checkpoint inhibition and of studies evaluating checkpoint inhibitors in humans. The review also details results and side effects from studies conducted with pediatric patients, current pediatric clinical trials, and future implications.

Conclusion: Immune checkpoint inhibitors have the potential to further therapeutic advances in pediatric oncology; however, we need more clinical trials and combination drug strategies targeted toward pediatric cancers.

Citing Articles

Insights into Personalized Care Strategies for Wilms Tumor: A Narrative Literature Review.

Karam S, Gebreil A, Alksas A, Balaha H, Khalil A, Ghazal M Biomedicines. 2024; 12(7).

PMID: 39062028 PMC: 11274555. DOI: 10.3390/biomedicines12071455.

Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy.

Belgiovine C, Mebelli K, Raffaele A, De Cicco M, Rotella J, Pedrazzoli P Int J Mol Sci. 2024; 25(6).

PMID: 38542199 PMC: 10970338. DOI: 10.3390/ijms25063225.

Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma.

Du S, Zhao Y, Hu Z, Liu S, Roy A, Shen J CPT Pharmacometrics Syst Pharmacol. 2023; 13(1):168-179.

PMID: 37873561 PMC: 10787196. DOI: 10.1002/psp4.13070.

Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.

Rohila D, Park I, Pham T, Jones R, Tapia E, Liu K Front Immunol. 2023; 14:1148317.

PMID: 37350973 PMC: 10283071. DOI: 10.3389/fimmu.2023.1148317.

Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells.

Yu E, Cheung N, Lue N J Hematol Oncol. 2022; 15(1):117.

PMID: 36030273 PMC: 9420296. DOI: 10.1186/s13045-022-01337-w.

References

Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999; 5(12):1365-9. DOI: 10.1038/70932. View

Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I . PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2(3):261-8. DOI: 10.1038/85330. View

Dong H, Strome S, Salomao D, Tamura H, Hirano F, Flies D . Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8(8):793-800. DOI: 10.1038/nm730. View

Brown J, Dorfman D, Ma F, Sullivan E, Munoz O, Wood C . Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003; 170(3):1257-66. DOI: 10.4049/jimmunol.170.3.1257. View

Blazar B, Carreno B, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H . Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003; 171(3):1272-7. DOI: 10.4049/jimmunol.171.3.1272. View

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R . Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003; 63(21):7462-7. View

Chemnitz J, Parry R, Nichols K, June C, Riley J . SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004; 173(2):945-54. DOI: 10.4049/jimmunol.173.2.945. View

10.

Sheppard K, Fitz L, Lee J, Benander C, George J, Wooters J . PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004; 574(1-3):37-41. DOI: 10.1016/j.febslet.2004.07.083. View

11.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

12.

Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, Tashima M . PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008; 111(6):3220-4. DOI: 10.1182/blood-2007-05-085159. View

13.

Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8(6):467-77. DOI: 10.1038/nri2326. View

14.

Chen X, Liu S, Wang L, Zhang W, Ji Y, Ma X . Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther. 2008; 7(5):622-7. DOI: 10.4161/cbt.7.5.5689. View

15.

Peggs K, Quezada S, Allison J . Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008; 224:141-65. DOI: 10.1111/j.1600-065X.2008.00649.x. View

16.

Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou L . B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009; 11(6):757-66. PMC: 2802396. DOI: 10.1215/15228517-2009-014. View

17.

Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A . B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 2009; 100(11):2093-100. PMC: 11158527. DOI: 10.1111/j.1349-7006.2009.01302.x. View

18.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

19.

Andorsky D, Yamada R, Said J, Pinkus G, Betting D, Timmerman J . Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011; 17(13):4232-44. DOI: 10.1158/1078-0432.CCR-10-2660. View

20.

Robert C, Thomas L, Bondarenko I, ODay S, Weber J, Garbe C . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517-26. DOI: 10.1056/NEJMoa1104621. View